Cellectis (NASDAQ:CLLS) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Cellectis (NASDAQ:CLLS) announced its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.04, Zacks reports. The company had revenue of $6.90 million during the quarter, compared to analyst estimates of $11.05 million. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%.

Cellectis Stock Down 2.4%

Cellectis stock opened at $3.24 on Friday. The stock has a market cap of $325.10 million, a PE ratio of -4.98 and a beta of 2.92. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.37 and a current ratio of 1.37. Cellectis has a one year low of $2.35 and a one year high of $5.48. The stock has a fifty day moving average of $3.03 and a 200 day moving average of $3.38.

Analysts Set New Price Targets

A number of analysts have commented on the company. Barclays began coverage on Cellectis in a report on Thursday, May 28th. They issued an “overweight” rating and a $9.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellectis in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $7.00.

Institutional Investors Weigh In On Cellectis

A number of large investors have recently made changes to their positions in the company. Global Retirement Partners LLC purchased a new stake in shares of Cellectis in the 4th quarter worth $34,000. Acadian Asset Management LLC lifted its position in Cellectis by 132.9% during the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 26,461 shares in the last quarter. Virtu Financial LLC purchased a new position in Cellectis during the third quarter valued at $72,000. Millennium Management LLC grew its holdings in Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after purchasing an additional 22,080 shares during the period. Finally, Citadel Advisors LLC bought a new position in shares of Cellectis during the 3rd quarter valued at approximately $633,000. 63.90% of the stock is currently owned by institutional investors.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.